论文部分内容阅读
目的:观察康艾注射液联合射波刀方案治疗原发性肝癌患者的临床疗效和安全性。方法:将50例患者按随机数字表达分为2组各25例。对照组予单纯射波刀治疗,观察组予康艾注射液联合射波刀治疗,观察2组近期疗效、Karnofsky评分、初次复发转移率及毒性反应。结果:2组治疗后近期疗效总有效率(RR)观察组为84.0%,对照组为56.0%,2组比较,差异有显著性意义(P<0.05);观察组治疗后Karnofsky评分高于对照组,2组比较,差异有显著性意义(P<0.05);观察组初次复发转移率低于对照组,2组比较,差异有显著性意义(P<0.05);毒性反应中观察组消化道毒性反应发生率、白细胞减少发生率均低于对照组,差异均有显著性意义(P<0.05)。结论:康艾注射液具有提高生活质量、增效减毒及防治肿瘤复发转移的作用,其联合射波刀方案治疗原发性肝癌效果明显优于单纯射波刀治疗的效果,是一种疗效肯定、安全可靠,具有推广价值的原发性肝癌综合治疗方法。
Objective: To observe the clinical efficacy and safety of Kangai injection combined with wave knife in the treatment of patients with primary liver cancer. Methods: Fifty patients were divided into two groups of 25 cases according to random number expression. The control group was treated with simple wave knife. The observation group was treated with Kang AI injection combined with wave knife. The short-term curative effect, Karnofsky score, initial recurrence and metastasis rate and toxicity were observed in the two groups. Results: The total effective rate (RR) in the two groups after treatment was 84.0% in the observation group and 56.0% in the control group, and there was significant difference between the two groups (P <0.05). The Karnofsky score of the observation group was higher than that of the control group (P <0.05). The initial recurrence and metastasis rate of the observation group was lower than that of the control group. There was significant difference between the two groups (P <0.05). In the toxicity group, the digestive tract of the observation group The incidence of toxic reaction and leukopenia were lower than those of the control group, with significant difference (P <0.05). CONCLUSION: Kangai injection has the effect of improving quality of life, increasing efficiency and reducing toxicity, and preventing and treating tumor recurrence and metastasis. The combination of wave-knife treatment for primary hepatocellular carcinoma is obviously better than that of simple wave-knife treatment and is a curative effect Sure, safe and reliable, with the promotion of the value of comprehensive treatment of primary liver cancer.